Latest News

SOUTH METRO DENVER CHAMBER: CBRE Report: Autonomous Vehicles Expected to Fundamentally Reshape U.S. Office Market by 2030

By disrupting the way employees commute to work, autonomous vehicles are expected to fundamentally reshape the U.S. office market by 2030, according to a new report from CBRE.

GOLFTEC: Are worn-out wedges hurting you?

Are your worn out wedges hurting your game- chip shotYou know this scenario: A tour player misses the green, grabs a wedge, lands the shot pin high and the ball bounces once before spinning back toward the hole like it’s on a string.

CARBON CHAMBER & ECONOMIC DEVELOPMENT CORPORATION: Sustainability Commission Looks At Recycling

At their November meeting, the Carbondale Sustainability Commission hosted a presentation by Keep Carbondale Beautiful on “The Future of Recycling in Carbondale.”

GLOBAL COMMUNICATIONS GROUP: Finding a Balance on Your IT Cybersecurity Spending

Cybersecurity has quickly gone from being viewed as security overkill to a necessity by most businesses.

GOLFTEC: Talking equipment with James Hahn at the 2018 PGA Championship

We talk equipment with James Hahn at the PGA Championship- James Hahn swing Two-time PGA Tour winner, James Hahn, on the range at the 2018 PGA Championship.

BALL CORPORATION: Ball to Expand use of Wind Power in Findlay, Ohio; Create Additional Local Sustainability Scholarships

Ball Corporation (NYSE:BLL) and One Energy Enterprises LLC announced plans today to build three additional wind turbines to provide power to Ball's Findlay, Ohio, beverage packaging plant.

AUREUS TECHSYSTEMS: Fighting Pharmaceutical Fraud with Blockchain

The large majority of pharmacies are honest businesses, but some have been responsible for deadly acts of fraud.

ARRAY BIOPHARMA: European Commission Approves Braftovi® (Encorafenib) in Combination woth Mektovi® (Binimetinib) for Advance Braf-Mutant Melanoma

Array BioPharma Inc. (NASDAQ: ARRY) today announced that the European Commission (EC) has approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test.

Metro Business Network